Table 3.

Secondary outcomes

	Clevidipine (n = 44)	Non-clevidipine (n = 53)	p-value
Time to control SBP within prespecified, minutes (median, IQR)	5 (2–7)	4 (4–4)	0.09
Need for surgical reintervention for bleeding/hematoma, n (%)	0 (0%)	0 (0%)	1
Incidence of clinically significant expansion hematoma, n (%)	1 (2.2%)	1 (1.8%)	0.20
ICU length of stay, h (median, IQR)	17 (16–20)	17 (16–18)	0.79
Hospital length of stay, days (median, IQR)	3 (2–4)	3 (2–4)	0.90
In-hospital mortality, n (%)	0 (0%)	0 (0%)	1